Click here to go to the previous page
Interactions of Radiation with Novel Chemotherapy and Biological Targeting Agents
Program Code:
EDU209
Date:
Monday, September 22, 2008
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Paul Harari,
M.D., Professor,
University of Wisconsin School of Medicine
Dr. Paul M. Harari is the Jack Fowler Professor and Chairman of the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health. Dr. Harari earned his Bachelors degree at Tufts University (1980) and Medical degree at the University of Virginia (1984). He completed his Internal Medicine Internship at the University of California Davis and Radiation Oncology Residency Training at the University of Arizona (1990). His clinical and laboratory research focuses primarily on treatment advances for head and neck cancer patients with emphasis on the interaction of molecular growth inhibitors combined with radiation. He serves as the Principal Investigator for a series of federal and industry sponsored research grants that examine the interaction of molecular growth inhibitors with radiation. Dr. Harari has served as Chairman of the ASTRO Education Committee (2004-2008) and on the ASCO Education and Program Committees. He directed the Radiation Oncology Residency Training Program at the University of Wisconsin from 1997-2007. Dr. Harari has authored over 150 original research articles and book chapters on cancer research topics with particular emphasis on the treatment of head and neck cancer.
|
Kevin Kozak, Assistant Professor, University of Wisconsin Cancer Center
George Wilson, Chief, Radiation Biology, Beaumont Hospital
LEARNER OUTCOMES:
-
Define basic biologic features of drug/radiation interactions.
-
Highlight novel biologic targeted therapies that show promise for combonation with radiation.
-
Identify future research oppurtunities for therapeutic advances with drug/radiation combonations.
-
Review examples of effective drug/radiation combonations in cancer therapy.